Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis

Systemic Sclerosis Clinical Trial

— Pre_MSC-AT-SSc  

Official title:

Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05947682
• Other study ID #: APHP230376
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 2023
• Est. completion date: February 2025

Study information

• Verified date: June 2023
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Dominique Farge, Pr
• Phone: +33142499768
• Email: dominique.farge-bancel[@]aphp.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Mesenchymal stromal cells (MSC) are multipotent cells which carry immunomodulatory, pro-angiogenic and anti-fibrotic properties, that can target Systemic Sclerosis (SSc) pathogenesis and its clinical manifestations. The increasing use of MSC, harvested from bone marrow (MSC(M)), adipose tissue (MSC(AT)), or umbilical cord (MSC(UC)) in a variety of indications, provides consistent evidence supporting their safety in humans. The efficacy of MSC(M) intravenous (IV) injection for treating acute graft versus host disease led to their marketing approval in 2012 and MSC(AT) (Alofisel) were approved for severe Crohn's fistula in 2018. MSC represent a promising therapeutic approach for SSc. We previously a) showed disease-specific abnormalities in MSC(M) from SSc patients, providing strong rationale to use allogeneic MSC to treat SSc patients, b) completed the first phase I/II dose escalation trial using allogenic MSC(M) infusion in 20 severe SSc patients (ClinicalTrials.gov: NCT02213705, PHRC AOM 11-250) with no safety issues, significant improvement in skin fibrosis at 3 to 6 months after infusion which appeared lower thereafter, thereby supporting the need for repeated infusions. In vitro, experimental and clinical studies suggest that MSC properties vary according to their tissue of origin/source. We demonstrated that compared to MSC(M), MSC(AT) are easier to harvest and display higher proliferative capability before entering senescence, higher genetic stability, and superior immunosuppressive properties. The objective of the present research is the successful production of allogeneic MSC(AT) derived from selected healthy donors, with adequate phenotypic criteria according to the International Society for Cell & Gene Therapy. Considering the above rationale, these MSC(AT) will subsequently be used in a Phase I/II randomized clinical trial testing allogeneic MSC(AT) systemic infusion for treatment of severe systemic sclerosis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 6
• Est. completion date: February 2025
• Est. primary completion date: February 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Age = 18 and = 55 years
• BMI <30
• Non-smoker
• Admission for a pre-scheduled plastic surgery intervention liposuction or lipo-aspiration in the abdominal wall under general anesthesia
• Written consent
• Affiliated to a social security

Exclusion Criteria:

• Weight < 50 kg
• Positive viral serology : Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Hepatitis E Virus (HEV), syphilis, Human T Lymphotropic virus (HTLV), active infection with IgM+ for toxoplasmosis, Epsiten Barr Virus (EBV), Cytomegalovirus (CMV)
• Active generalized infection (viral, parasitic, tuberculosis, leprosy...)
• Significant comorbidities according to donor health history or existing risk factors

for viral infections within the past 12 months:

• Multiple sexual partners between the donor or his or her usual partner
• Intravenous addiction to the donor or regular partner
• Accident of exposure to blood or derivatives suspected of being contaminated
• Uncontrolled hypertension
• Human dura mater transplant
• Surgical history of the central nervous system
• Dementia or neurological disease that may evoke subacute spongiform encephalopathy
• Family history as part of subacute spongiform encephalopathy
• Hematological malignancies
• Active or any past history of cancer
• History of chemotherapy or irradiation
• Systemic or autoimmune disease
• Multiple adenopathy, splenomegaly, hepatomegaly
• Icterus
• Haemophilia
• Known insulin-dependent diabetes
• Treatment with extractive pituitary hormones (including growth hormones)
• Steroids therapy (for more than 5 days) in the past 3 months
• Lithium treatment
• Pregnancy
• Deprived of freedom

Related Conditions & MeSH terms

• Scleroderma, Diffuse
• Scleroderma, Systemic
• Sclerosis
• Systemic Sclerosis

Intervention

Other:
• Adipose tissue harvesting
Adipose tissue harvesting (40-60g) during the abdominal liposuction or lipoaspiration under general anaesthesia which is performed according to usual care

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Production of at least 3 batches of MSC(AT) derived from donors adipose tissue		Up to 2 months
Secondary	Percentage of viability		Up to 2 months
Secondary	Percentage of CD73+ cells		Up to 2 months
Secondary	Percentage of CD90+ cells		Up to 2 months
Secondary	Percentage of CD105+ cells		Up to 2 months
Secondary	Percentage of expression of HLA-DR		Up to 2 months